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Abstract 
Humans are faced with a vast number of pathological conditions.  Some the 
most prevalent and deadly disease states include cancer, obesity, and diabetes.  A 
large amount of scientific research and development has gone into determining the 
underlying cause of these pathologies.   Certain aspects of the aforementioned 
diseases have been linked to the aberrant expression and activity of selected gene-
expression-programs.  Gene expression is regulated by proteins known as 
transcription factors.  One of the largest transcription factor families is the nuclear 
receptor (NR) superfamily.  The ability of NRs to drive gene activation is directed by 
specific interacting proteins called cofactors.  This review will highlight new 
discoveries regarding the mechanistic role of NRs and their associated protein 
cofactors in regulating gene activation and in the progression of cancer, diabetes, and 
obesity.   
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Introduction 
Several types of nuclear receptors exist in cells which are responsible 
for the transcription of genes.  NRs have been divided into classes based on 
the receptor-ligand interaction or the receptor’s structure.  Structurally, NRs 
are made up of an N-terminal activation function domain (AF-1), a DNA 
binding domain (DBD), a hinge region, and the C-terminal which contains the 
ligand binding domain (LBD) which contains a second activation function 
domain, (AF-2).  These attributes are found in the all NRs. 
NRs can be categorized into two main classes based on the mechanism 
of action and sub-cellular location.  NRs can be broken down into types of 
receptor classes that include Type I, Type II, and orphan receptors.  Type I 
NRs feature the classic steroid hormone receptors glucocorticoid receptor 
(GR), estrogen receptor (ER), and androgen receptor (AR).   This type of 
receptor goes through a nuclear translocation upon hormone binding and 
associates with a consensus sequence on DNA as a homodimer.  This nuclear 
binding is found to recruit coactivator proteins to aid in the gene expression. 
Type II receptors include retinoic acid receptor (RAR), retinoid X 
receptor (RXR), thyroid hormone receptor (TR), and vitamin D3 receptor 
(VDR) among others.  This class of receptors resides in the nucleus, and 
regardless of a ligand binding event, will heterodimerize with other NRs on 
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their binding sites.  In the absence of ligands, Type II receptors are usually 
associated with corepressor proteins.  This association inhibits or represses 
gene expression.  When a ligand is bound to Type II receptors, the corepressor 
proteins are disassociated, which allows for gene expression to proceed. 
A third family of NRs, designated orphan receptors, was identified 
through the use of low stringency screening methods and conserved sequences 
of NR cDNAs.  These orphan receptors share a high structural homology with 
other NRs but do not have an intrinsic physiological “parent” ligand.  The 
orphan receptors interact with both corepressors and coactivators but not in a 
clearly defined role as the other two classes. 
All three classes of NRs modulate gene expression through 
interactions with cofactors.  NRs react to the cells’ environment and rely on 
cofactors to drive proper gene expression.  The cofactors interact with NRs to 
enhance their ability to activate or repress transcription.  It is becoming 
increasingly clear that these cofactors connect many diverse biological 
processes with NR-mediated transcription in a cohesive, but poorly 
understood communication network. 
Cofactors represent a diverse group of proteins that serve to enhance 
NR-mediated transcription primarily by binding to the ligand-activated 
receptor.  Cofactors can be broken into two groups, the corepressor and the 
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coactivator.  The corepressor was originally defined by its ability to inhibit 
transcription while the coactivator promoted the initiation of transcription.  
Unlike NRs, which adhere to a common structural theme, cofactors are highly 
diverse and have expanded to more than 300 in number.  They can serve as 
adapters between the receptor and the general transcription machinery.   
Two main ideas about cofactor functions have emerged regarding the 
relationship between cofactors and NR interactions.  The first idea that 
became apparent was that enzymatic activities and structures are required for 
transcription.  Enzymatic activities and structures are not only required for 
transcriptional function but also for modification of the integral components 
of the multiprotein complexes involved in transcription.  These complexes 
also have been shown to be involved in modifications of the components of 
the basic transcriptional apparatus, specifically gene promoters.  For example, 
many cofactors interact with the NR ligand binding domain (LBD) through a 
highly conserved NR box, or short amino acid motif.  This NR box is made up 
of a LXXLL motif, (where L represents leucine, and X corresponds to any 
amino acid), that forms an amphipathic alpha helix [1, 2].  The combination of 
the specific LXXLL motifs and flanking sequences influence the structural 
patterns of usage by different NRs [3].   
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The second idea about cofactor function to emerge is that many 
regulated transcription factors use a precise, almost step wise, sequence of 
functional actions by multiple protein complexes for mediating gene 
expression.  The biological actions of post translational modifications (PTMs) 
permit cofactors to perform in a scheduled fashion.   Many of the sequential 
PTMs are responsible for the specific gene expression responses to biological 
signals.  These modifications are needed for gene activation or gene 
deactivation.  Yet, for these modifications to start gene expression, the 
interaction of cofactors with NRs requires a recognition interface between the 
proteins.  This primary recognition interface is between the LXXLL motif and 
the NR. 
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Transcriptional Dynamics of NRs through the LXXLL Motif 
The regulatory sequences of NR-target genes are normally 
incorporated into the tightly bound chromatin structure that is independent of 
gene expression.  This configuration allows for an agonist binding event to 
trigger a conformational change in structure of the NRs.  The area in which 
this conformational change occurs is in the NR region of the AF-2.  This leads 
to the recruitment of cofactors through the LXXLL motif and promotes 
transcriptional activation.  
The structural causes for signal dependent cofactor interactions have 
been intensively studied with regards to nuclear receptors and the interactions 
of the LXXLL motif.  The nuclear receptor LBD consists of three inner core 
alpha helices and two outer core helices.  The central core of these three 
helices is packed between two additional layers of helices which form the 
ligand-binding cavity.  An additional helix required for ligand-dependent 
transcriptional activation resides at the C terminus of the LBD and assumes 
different positions depending on the presence or absence of ligands [4].  This 
activation helix assumes a different configuration in the presence of agonists.  
This agonist inspired helical configuration is called a “charge clamp" [5]. 
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In the presence of an agonist, the AF-2 helix is stabilized in the active 
conformation that forms the charge clamp pocket and facilitates the binding of 
the coactivator helix.  In contrast, the binding of an antagonist keeps the AF-2 
helix out of the active position, resulting in a larger pocket that destabilizes 
coactivator binding.  The AF-2 helix consequently serves as a ligand sensor to 
regulate NR functions involved in gene expression through interaction with 
the LXXLL motif. 
Several cofactors have been shown to contain the LXXLL motif, with 
single or multiple copies of the sequence forming the NR interacting domain.  
The number of the LXXLL motifs also varies considerably among cofactors 
and is likely to account for the observed differences in binding to selected 
NRs.  The motif, or a form of it, is involved in regulating the interaction of 
NRs with both coactivators and corepressors.   
Corepressors that have this motif include the nuclear receptor 
corepressor (NCoR) and silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT).  Both NCoR and SMRT interact with unliganded 
nuclear receptors through an elongated LXXLL motif, e.g. LXX I/H IXXX 
I/L, (I represents isoleucine and H represents histidine).  This elongated 
LXXLL motif is alternatively referred to as the Cornr-box [6, 7].  In the 
absence of agonist binding, this extended helix can fill the same hydrophobic 
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pocket in the NR that is occupied by the LXXLL motif due to the 
displacement of the AF-2.  However, the extended helices of NCoR/SMRT 
are too long to be accommodated by this pocket when the AF-2 assumes the 
charge clamp configuration in response to ligand binding.  Therefore, ligand 
binding reduces the affinity of corepressors that have the Cornr-box motif.  
This increases the affinity for the shorter LXXLL sequence containing 
coactivators [6, 7]. 
Other NR corepressors are recruited by the LXXLL motif in a ligand-
dependent manner.  For example, ligand-dependent nuclear corepressor 
(LCoR), receptor interaction protein 140 (RIP140), repressor of estrogen 
receptor activity (REA), and the preferentially expressed antigen in 
melanoma, (PRAME), are each recruited to nuclear receptors in a ligand 
dependent manner through interaction with LXXLL helices [8-11].  The 
LXXLL motifs, which may be used in a nuclear receptor specific fashion, can 
permit allosteric effects to modulate the efficacy and the stability of 
coactivator function [12]. 
The cofactor motif LXXLL functions to aid in the regulation of the 
gene expression of NR target genes.  Interaction of this cofactor motif is not 
the only way that cofactors are able to regulate NR responses.  Cofactors are 
able to respond to endocrine signals as well as regulate the stability, 
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localization, and PTMs of NRs.  For this to occur, many cofactors have a 
shared characteristic in their enzymatic activities that promote and direct 
transcription through PTMs.  For instance, in the p160 family or cofactors 
known as steroid receptor coactivators (SRC-1, 2 and 3) PTMs are integral to 
many of the activities required for gene expression.  SRC-1 and 3, along with 
cAMP response binding element (CREB)-binding protein (CBP), and p300 
contain histone acetyltransferase (HAT) activity that targets histones or other 
proteins at NR-regulated gene promoters for acetylation. 
Post-translational Modifications of Cofactors 
Histones are a major site for regulation of gene expression by 
cofactors.  The targeting of histones by cofactors with PTMs causes the genes 
to activate or deactivate.  However, histones are not the only targets of 
cofactor PTM actions.  Cofactor PTMs lead to distinct biological responses.  
These responses affect the histones embedded in the chromatin and 
transcriptional expression [13-16].  
PTMs can also lead to the epigenetic modification of DNA.  
Modifications of histones can be directed to a specific gene locus and will 
influence the expression of an individual gene.  This influence happens 
through the PTM’s ability to modulate multiple gene sets that are targeted by 
a wide variety of transcription factors.  These physical interactions direct the 
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role of cofactors to assemble a variety of gene products to organize different 
functions towards a physiological goal.  It is apparent that the DNA, 
chromatin proteins, transcription factors, cofactors, and signaling enzymes all 
communicate with each other.  This communication occurs through reversible 
covalent modifications which provide a complicated, but critical signal 
integration of individual proteins that direct cell dynamics. 
Biological complexity and environmental signal integration can be 
seen in many cofactors.  For instance, SRC-3 can be modified by a small 
ubiquitin-related modifier protein or SUMOylated (at aa 723 and 786) and is 
phosphorylated at threonine/serine residues (at aa T24, S505, S543, S857, 
S860, and S867).  After phosphorylation events at serine 505/509 in a 
glycogen synthase kinase 3 (GSK3)-dependent manner, SRC-3 becomes 
monoubiquitinated at amino acids 723 and 786, and is able to function as a 
potent and specific transcriptional activator [15, 17-21].  The ubiquitination 
sites are gradually polyubiquitinated during subsequent rounds of 
transcription, ultimately leading to its degradation by the 26S proteasome 
[22].  Yet, other phosphorylation sites in SRC-3 are targeted by other kinases 
and are necessary for SRC-3 to form different multiprotein complexes and 
coactivate more of its targeted transcription factors [19, 23].  In SRC-3, other 
PTMs such as methylation or acetylation lead to cofactor complex 
disassembly, which along with proteasome-mediated degradation, contributes 
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to coregulator component interactions by altering its transcriptional properties 
[24, 25].  
Ubiquitin and SUMOylation mediated processes have functions in 
cofactor activity involved with proteasome-mediated degradation.  For 
example, ubiquitin plays a critical role in regulating cofactor activity which 
induces proteasome-mediated degradation of the protein by directly altering 
its transcriptional properties.  SUMOylation is involved with the subcellular 
localization of cofactors and affects the stability and activity of cofactors 
through proteasome-mediated degradation.  The further roles of SUMOylation 
and ubiquination in regards to cofactors and PTMs are currently under 
investigation.  Other forms of PTMs and cofactor interactions, such as 
phosphorylation, have been studied for a long time. In the case of SRC-3 six 
phosphorylation sites are necessary for activation of different NRs.  
Phosphorylation of these six sites in SRC-3 can also activate other cofactors.  
However, not all of these sites are required for coactivation of other cofactors.  
Different combinations of site-specific phosphorylation of SRC-3 are 
necessary for regulation of endogenous genes involved in inflammation or 
transformation.  Biochemical studies support the concept that modulation of 
SRC-3 phosphorylation alters its interactions with potential other cofactor 
partners, allowing the partners to function as a regulated integrator for diverse 
signaling pathways [15, 20, 21].  This is seen when phosphorylation of several 
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residues of SRC-3 are required for its effective interaction with the cAMP 
response element binding protein (CREB) binding protein (CBP) [20, 24, 26-
28]. 
Two closely related cofactors, CBP and p300, can directly interact 
with NRs through the receptor interaction domain at the N-terminal.  This 
domain appears to be non-essential for transcriptional activation in vitro [29].  
The CBP/p300 cofactors are mainly recruited indirectly with SRC-1and 3 to 
NR target genes.  These cofactors through HAT activity serve as assembly 
points for multiple activation complexes of ligand-dependent activation of 
NRs [30]. 
Many proteins interact with multiple cofactors, and these cofactor-
cofactor interactions enhance transcriptional activity.  An example of this type 
of interaction was seen with cofactor interactions and the glucocorticoid 
receptor interacting protein 1 (GRIP1) [31].  The p160 family showed that 
these interactions occur through the coiled-coil coactivator A (CoCoA) and is 
bound to the basic helix loop helix (bHLH) in the period circadian protein/Ah 
receptor nuclear translocator protein/single-minded protein (PAS) domain of 
GRIP1.  This binding interaction of p160s and GRIP1 was shown to enhance 
the transcriptional activation of  NRs [28].  This type of activity further 
showed the importance of other cofactor-cofactor interactions and 
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transcriptional activity.  The discovery that coactivator associated arginine 
methyltransferase 1 (CARM1) can interact with GRIP 1 helped to uncover 
other pathways involving the p160s.  These two proteins interact on the AF2 
domain and demonstrate activity of histone methylation into NR-activation 
networks [31].  
CARM1 exhibits intrinsic protein arginine methyltransferase activity.  
This activity is responsible for modifying Arg 17 on histone H3, and these two 
factors together boost the activation of transcription.  The increase in 
activation occurs when recruited hormone activated transcriptional complexes 
are interacting with the p160 proteins.  Protein arginine methyltransferase 1 
(PRMT1), another type of arginine specific protein methyltransferase, acts on 
histone H4.  PRMT1 was also found to be a coactivator for NRs [16, 32].  
PRMT1, like CARM1, binds to the C-terminal activation domain of the p160 
coactivators, and this interaction combines to synergistically stimulate 
transcription by NRs with CBP/p300 in transient transfection assays [16, 32].  
CARM1 and GRIP1 specifically associate with a large tandem array of mouse 
mammary tumor virus (MMTV) promoters in a ligand-dependent manner to 
enhance gene expression.  However, lysine methylation at K4 in histone H3, 
which is often associated with transcriptionally competent chromatin, is not 
affected by hormone treatment.  This work suggests that arginine specific 
histone methylation by CARM1 is an important step in transcriptional 
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activation at NR target genes [33].  CARM1 has been shown to regulate a 
number of nuclear hormone receptors and the use of the chromatin 
immunoprecipitation assay (ChIP), coupled with promoter arrays, can be 
helpful in understanding the larger role of arginine methylation in activating 
NR target genes. 
Numerous studies support the idea that arginine methylation correlates 
with transcriptional activation.  An interesting feature of this modification is 
the retention of a positive charge, as opposed to acetylation, which neutralizes 
the positive charge of lysine. Whether methylated arginine alters the higher 
order of the chromatin structure or serves as a marker for recruitment of 
additional proteins is unknown.  Even so, it has become clear that different 
histone modifications by cofactor proteins are an integral part of gene 
regulation.  It has been established that the interactions between histone 
methylation by CARM1 and PRMT1 and histone acetylation by CBP/p300 are 
important for the expression of NR target genes. Although methylation of 
Arg3 by PRMT1 eases further acetylation events of H4 tails by p300.  These 
ordered cooperative functions of PRMT1 and CARM1 are not restricted to 
NR pathways, as these interactions have also been observed in transcriptional 
activation by p53 [16, 32]. 
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CBP acetylates SRC-3 through its receptor interaction domain.  This 
discovery provided a new idea of transcriptional regulation through 
acetylation [34].  This idea suggests that a built-in mechanism may exist that 
enables the hormone response to be attenuated in both a ligand and receptor-
dependent fashion.  Yet, methylation of CBP by CARM1 has a different 
outcome.  CARM1-mediated methylation of CBP in the CREB binding 
domain (KIX) stops interaction with CREB, resulting in the inhibition of 
CREB-dependent transcription.  This differs from the normal action of 
CARM1 and CBP where these two coactivators act together to increase the 
coactivated transcriptions by NRs.   In these examples, CARM1 appears to be 
a molecular switch that selectively blocks cAMP signaling while it potentiates 
NR-mediated transcription [16].  Subsequent studies have revealed that 
CBP/p300 can be methylated by CARM1 at other sites, which are important 
for the coactivator communications which will activate NRs.  
Many PTMs serve to enhance the role of cofactors for the activation of 
NRs.  Post translational events such as, methylation, acetylation and 
phosphorylation direct the transcriptional activity for intricate signaling 
pathways required for gene expression.  Taken together, an increasing number 
of cofactor modifications are emerging, which affect complex assembly and 
mediate a broad array of transcriptional responses.  The cofactors are the 
assembly point for multiple protein complexes and precipitate the 
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transcriptional events involved in gene expression.  There are instances when 
cofactors are able to reverse their normal function in certain circumstances. 
Modifications which Cause Role Reversals in Some Cofactors  
Some cofactors can function as both coactivators and corepressors.  
One such example is GRIP1, which normally functions as a coactivator of 
nuclear receptors.  Yet, GRIP1 can function as a corepressor in combination 
with a bound estradiol receptor [35].  When this occurs there are allosteric 
influences in the DNA-binding hormone response element which regulate the 
ability of GRIP1 to bind unique parts of GR.  These allosteric events are able 
to change its role from coactivator to corepressor [36]. Two corepressors, 
SMRT and NCoR, have illustrated a role reversal in certain situations.  SMRT 
and NCoR can function as coactivators in specific promoter cofactor 
interactions.  This demonstrates that these cofactor proteins can enhance or 
repress gene expression in a gene specific manner [37].  One example of role 
reversal is seen in SMRT.  When SMRT is bound to TRα it undergoes a 
conformational change in a manner that causes an increase in the reaction of 
hormone response elements.  Changes in the structures of NCoR and SMRT 
have been reported to impact the biological actions of various proteins as well.  
These changes suggest that PTMs have the ability to change the 
transcriptional effects of these corepressors [38].   
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Cofactor functions can be modulated by conformational changes as 
seen with SMRT.  Cofactors can also be regulated by PTMs.  The 
modifications highlight the complex integrations of upstream signals.  In 
certain cases PTMs can alter the function of a corepressor such that it 
becomes a coactivator.  An example of PTM role reversal is seen in the 
corepressor, RIP140.  This role reversal occurs to RIP140 when it is 
conjugated to vitamin B6 through arginine methylation and phosphorylation.  
These PTMs modify RIP140’s repressive function through direct competition 
with coactivators for agonist bound receptors.  RIP140 is able to directly 
oppose the transcriptional activity of agonist ligands [39, 40].  This opposition 
allows for an alternative way of transcription that is distinct from the SMRT 
role reversal [41]. 
Role reversals are seen in the steroid receptor RNA activator (SRA) in 
certain situations.  A role reversal in SRA is based on the phosphorylation of 
two specific proteins.  These proteins may function in a manner to control 
whether SRA positively or negatively influence gene transcription through 
phosphorylation [42].  The example of SRA shows that a functional role 
reversal in a coregulator’s action can be driven by its PTMs status.  The action 
of PTMs on cofactors illustrates coregulator dynamics that are present in the 
cell [13, 14].  Cofactors perform role reversals through conformational 
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changes or PTMs and are an important mechanism involved in the molecular 
biology of gene expression.  
Cofactor PTMs as a Mechanism of Gene Expression in Molecular Biology 
Gene expression is achieved by the regulation of transcription and is 
needed for cell survival.  The regulation of transcription is accomplished 
through timing events from multiple signaling pathways.  The translation of 
the signals from the environment to gene expression is guided by PTMs in 
several types of transcriptional events.  A single PTM, such as 
phosphorylation, to a cofactor can be responsible for the effects of proper 
timing of gene expression, an immune response, and degradation transcription 
machinery operation [43].  .    This section is on timing so you need to 
introduce and focus on timing in this paragraph. Give your reader some idea 
of what will be discussed in this section. 
Phosphorylation events define SRC-3 association with other members 
of the transcription complex, such as p300 and CBP or CARM1 [15].  The 
diverse physiological functions of SRC-3 can be attributed to its multiple 
phosphorylation sites.  The six phosphorylation sites allow for the 
incorporation of multiple cellular signaling pathways to proceed with protein 
expression in the same time that the signals are being received [21].  The 
timing of the phosphorylation of a specific sequence on SRC-3 defines which 
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transcription factors this coactivator is able to activate and the time of 
activation [15].  This implies that the selectively phosphorylated factor is 
forced to preferentially implement the expression of genes downstream of a 
particular signaling cascade.  PTMs such as these casts a light on the role 
cofactors have at being the directors of multiple cell signaling systems.  
Activation of membrane receptors and signaling cascades then allow the 
genome to sense the impact of the total environment on the cell. 
PTMs of coactivators can enhance the timing of events in 
transcription.  Covalent modifications including phosphorylation, acetylation, 
sumoylation, ubiquitination, and poly(ADP ribosyl)ation of coactivators such 
as CBP are critical aspects of a stepwise timing function [13, 15, 16, 32].  This 
stepwise function is seen when the CREB activates the transcription of target 
genes.  The activation occurs through direct interactions with the KIX domain 
of the coactivator CBP in a phosphorylation-dependent manner [44-46].  The 
complex is formed first by the phosphorylated kinase inducible domain 
(pKID) of CREB.  The pKID undergoes a coil-to-helix folding transition upon 
binding to KIX.  This binding event causes a conformational change which 
forms two helices in pKID.  One helix of pKID is amphipathic and interacts 
with a hydrophobic groove defined by the structure of KIX.  The second 
pKID helix contacts a different segment of the KIX where a critical phosphate 
group of pKID forms a hydrogen bond to the side chain of the Tyr 658 in the 
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KIX structure.  This combination provides a model for phosphorylation-
dependent interactions between other transactivation domains and their targets 
in a stepwise manner [44-46].   
Cofactors can organize the expression of functional groups of genes 
involved in the implementation of a specific regulatory regime, such as the 
inflammatory response.  Members of the NF-κB family regulate a large 
number of genes involved in immune responses, specifically inflammation.  
This inflammation is mediated by IkappaB Kinase (IKK).  These kinases are 
able to modulate the corepressor, SMRT, by phosphorylation [47].  IKK 
phosphorylates SMRT, permitting ubiquitination and export from the nucleus, 
and this appears to occur in a cycling mode [48].  Separately, IKK 
independent of cofactor function can cause S10-H3 phosphorylation and also 
controls acetylation of K14-H3.  These PTMs suggest specialized functions of 
inflammatory cytokines are required for the regulation of  inflammation at 
specific times [49]. 
The stepwise building of multiprotein complexes is important for the 
proper transcriptional events.  It is critical to note that the degradation of these 
complexes is needed for future transcriptional events to proceed.  Protein 
degradation is mediated through the ubiquitin proteasome (Ub) and constitutes 
a new concept in which transcription is fine tuned.  Ub, along with 
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ubiquitinating enzymes and the proteasome, have been implicated in 
transcriptional regulation, which is sometimes independent of any degrading 
function.   
Early reports suggested the Ub conjugating enzyme (Ubc9) interacted 
with GR [50].  Several NRs, such as GR, androgen receptor, and PPARs, have 
subsequently been found to be modified by SUMO 1.  These modifications 
are mediated by Ubc9, and often coincide with the repression of NR 
transcriptional activity.  Furthermore, if SUMO 1 modification is blocked by 
mutations on Ubc9 or the corresponding NRs, Ubc9 can act as a coactivator 
for NRs.  This indicates that Ubc9 modulates NR activity regardless of its 
ability to catalyze SUMO-1 conjugation through degradation of protein 
complexes [51]. Degradation of proteins is needed to modulate the 
transcriptional activation for gene expression.  For gene expression to occur, 
the chromatin structure has to be remodeled in exact locations.  The activation 
of NR target genes requires direction of ATP-dependent chromatin 
remodeling complexes at these sites. 
ATP Dependent Chromatin Remodeling Interaction with NRs  
The chromatin structure in the eukaryotic nucleus creates barriers for 
transcription.  Changes in chromatin, such as the disruption or reassembly of 
nucleosomes, are mediated by large multiprotein modules called chromatin-
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remodeling complexes.  ATP dependent chromatin remodeling complexes use 
energy from ATP hydrolysis to increase the mobility of nucleosomal DNA.  
This regulates a variety of cellular processes including transcription, DNA 
replication, DNA repair, and recombination.  These complexes can be divided 
into 4 families according to the identity of their core ATPase subunits.  Two 
of the most studied family members with NR interactions are the 
switch/sucrose non-fermentable (SWI/SNF) and imitation SWI (ISWI) [52].  
The understanding of the mechanisms of chromatin remodeling and the 
biochemistry of individual functions of these different subunits is increasing 
rapidly.  
ATP-dependent chromatin-remodeling complexes have been tied to 
transcriptional regulation by steroid receptors for more than 15 years [53, 54].  
Initial reports indicated that GR and ER interact with the SWI/SNF 
remodeling complex [55].  The targeting of SWI/SNF is thought to be 
achieved through the interaction of DNA-binding transcription factors, 
cofactors, or general transcription machinery.  In addition, certain subunits of 
SWI/SNF with bromodomains are known to readily bind to acetylated histone 
tails.  Different SWI/SNF components have been shown to act in an 
intermediary fashion with critical interactions between ER and mammalian 
SWI/SNF subunits.  Researchers have looked at the context of NR cofactor 
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complexes and found multiple interactions were involved in the recruiting and 
stabilization of SWI/SNF on NR target gene promoters [55].   
Depending on the step of transcription, one or more subunits might 
play dominant roles in docking SWI/SNF.  The ChIP assay has made it 
possible to determine the specific recruitment of different factors and 
complexes by NRs, of which RAR/RXR and ERs have been extensively 
studied [56, 57].  Also, the use of immunofluorescence technology has 
allowed investigators to observe the dynamics of NR and chromatin 
interactions.  One such example of this chromatin interaction was with the 
GR.  The GR interacts rapidly with hormone response elements in living cells.  
Experiments have shown that GR first binds weakly to glucocorticoid 
response elements located throughout nucleosomes.  These nucleosomes 
target the SWI/SNF complex and result in histone reorganization [55, 58].  
The transiently remodeled chromatin creates a higher affinity cavity for 
additional GR binding.  The resulting chromatin reverts to the basal state 
through displacement reactions.  This suggests that the interaction between 
receptors and chromosomal regulatory elements during chromatin remodeling 
is not only a complicated process, but that it is also a reversible process.  
In addition to the SWI/SNF complex, other chromatin remodeling 
complexes such as ISWI, and nucleosome remodeling and deacetylation 
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(NURD), play a crucial role in NR function.  ISWI has been found to be the 
earliest remodeling complex recruited by activated retinoid receptors on a 
reconstituted chromatin template [57].  Activation of minichromosomes 
assembled with the MMTV promoter requires the progesterone receptor to 
bind to ISWI, but not SWI/SNF.  This event illustrates a chromatin 
remodeling event which helps to provide access by another transcription 
factor [53, 59].  The NURD complex, however, can be recruited to the ER by 
metastasis-associated gene 1 (MTA1).  The consequence of NURD 
recruitment is the repression of ligand-dependent transcription through the 
ER.  ER dependent transcription by the NURD complex happens because it 
contains at least two histone deacetylase complexes [16].  
Histone exchange and displacement can be mediated by the 
transcription elongation complex and by ATP-dependent remodeling enzymes 
[60].  This has been seen in vivo throughout the S. cerevisiae genome where a 
partial depletion of histones H3 and H4 tetramers have been observed [61].  
Histone depletion phenomenon is also observed with the progesterone 
receptor (PR).  Receptor-bound progesterone recruits SWI/SNF to the 
promoter in the cell after progesterone treatment.  SWI/SNF displaces histone 
H2A and H2B from nucleosomes containing the receptor binding sites, but not 
from adjacent nucleosomes.  The main reason for this displacement is within 
the actual DNA sequence.  It appears that the SWI/SNF promotes nucleosome 
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sliding on assembled ribosomal DNA without the displacement of H2A and 
H2B.  This information suggests the remodeling by SWI/SNF depends on the 
actual nucleotide sequence in the nucleosomes [62].  Given that NR-activated 
genes respond quickly to ligand treatment, the actively transcribed genes may 
be identified by histone variants.  Identification of histone variants is an 
important step in understanding the roles of NR driven transcription through 
remodeling proteins.  Abnormalities in Transcription and actual gene 
expression are an underlying cause in many of the disease states seen in many 
humans today.   
Cofactors and Diseases 
Many human diseases can be associated with faulty expression of 
cofactors or the incorrect interactions of transcriptional events.  This is seen in 
aggressive breast, uterine, ovarian, and prostate cancers.  In these types of 
cancers estrogen and androgen are both known to be powerful mitogenic 
factors.  In certain situations these factors can activate coregulators to promote 
unchecked cellular growth.  The p160 proteins, specifically SRC-3, are 
closely involved in the uncontrolled promotion of cancer.  SRC-3 was first 
identified as the coregulator amplified in breast cancer 1 (AIBC1) [63].  Many 
other cofactors have been found to be over expressed in cancers while other 
cofactors are involved in oncogenesis [8, 63-65].   
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Cofactor interactions are revealing themselves in other human 
pathologies in addition to cancer.  Studies have identified peroxisome 
proliferator activated receptor gamma coactivator 1 alpha (PGC-1 α) as a 
cofactor that has multiple partners to interact for activation or repression.  
PGC-1, originally identified as a PPARγ interacting coactivator in brown 
adipose tissue, has now been demonstrated to coactivate many NRs and 
several other transcription factors [66, 67].  PGC-1α has recently been shown 
to be methylated by PRMT1 [68].  The timing of many PGC-1α actions are 
potentiated by PRMTl-mediated methylation.  Understandably, mutations on 
PGC-1α methylation sites compromise its ability to activate transcription.  For 
instance, polymorphisms in PGC-1α are reported to be linked to diabetes, 
polycystic ovarian syndrome, and other metabolic syndromes [69, 70].  PGC-
1α is a key coactivator in the regulation of metabolic function [71].  Its 
expression is highly induced in brown adipose tissue and muscle during 
exercise, fasting, or cold exposure [66].  PGC-1α coactivates PPARγ, as well 
as other NRs, and it was shown to have a central role in metabolic function 
when knocked out in mouse models [72, 73].  The related protein, Peroxisome 
proliferator-activated receptor gamma coactivator 1 beta (PGC-1β), also 
functions as a metabolic coactivator.  PGC-1β knockout mice have defects in 
fat metabolism and mitochondrial function [74, 75].  
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Problems with obesity are directly related to energy metabolism.  
members of the p160 family function in energy metabolism through the NR 
PPARγ.  PPARγ is essential for adipoctye differentiation and correct energy 
homeostasis.  SRC-1 and SRC-2 have been shown to occupy opposite roles in 
energy metabolism in mice knockout studies.  In these knockout studies, a 
relationship with PPARγ was established.  Knockout mice of SRC-1 are prone 
to obesity due to decreased energy expenditure, whereas SRC-2 knockout 
mice are leaner due to the reduced transcriptional capacity of PPARγ.  Also, 
SRC-2 knockout mice have a distinct increase in the PGC-1α/SRC-1 
interaction.  This interaction enhances the thermogenic actions of PGC-1α in 
brown adipose tissue through PPARγ interactions in metabolism [76].   
SRC-3 is involved in energy metabolism by promoting the formation 
of white adipose tissue.  SRC-3 knockout mice possess a decreased adipose 
tissue mass [77].  Through knockout animal studies it was determined that 
SRC-3 is able to enhance CAAT enhancer binding protein β (C/EBPβ) 
mediated transcription of PPARγ.  While our understanding in this area 
grows, the complete interactions involved in energy homeostasis are still 
unknown.   
PPARγ is known to be directly involved with the cofactor PGC-1α in 
the differentiation of adipose tissue and energy metabolism.  Other cofactors, 
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such as RIP140, are also involved in energy metabolism.  RIP140 can repress 
the transcription of a variety of genes involved in fat and carbohydrate 
metabolism.  Loss of RIP140 in knockout mice causes a leaner phenotype, 
resistance to obesity, and increased insulin sensitivity [78].   
Conclusions  
The complex coordination of gene expression by NRs in response to 
diverse physiological, metabolic, and environmental cues requires the 
recruitment of functionally distinct cofactors and chromatin remodeling 
complexes.  The combination of these proteins in transcriptional regulation 
has been shown to be receptor dependent, ligand specific, and promoter to 
gene-specific.  The cell and tissue expression of cofactors have a dramatic 
impact on gene expression.  For example, PGC-1α is expressed in highly 
oxidative organs, such as the heart, muscle, brown fat, kidney, and liver.  
Animal studies that have used cold or fasting as experimental conditions show 
PGC-1α expression is dramatically induced.  This induction shows the ability 
of PGC-1α to regulate the metabolic process.  Many of the p160 family of 
proteins and PGC-1α have been shown to potentiate transcription by NR 
coactivators [76, 79].  Yet, it is important to observe that some coactivators 
appear to regulate a subset of NRs while others are more general in function.   
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Our initial understanding of cofactor function was simplistic as to 
center only on their role in the activation or repression of gene expression.  
Cofactor PTMs show the complex nature of the interactions by turning on and 
off genes.  PTMs influence the specific nature of the transcriptional response 
when exposed to distinct signaling conditions.  At this time it is impossible to 
determine the exact widespread effects these modifications will have on a 
biological system.  It stands to reason that broad NR functions will follow the 
same pathways in similar systems for fine tuning the transcriptional 
expression in biological models.  Studies from knockout mice and ChIP 
assays show a more complete role for cofactors in the recruitment of 
numerous proteins to the transcription complex.   Coactivators are organized 
in vivo into complexes that are primed for recruitment by NRs.  Studies have 
shown and support the sequential coactivator recruitment model.  In this 
model, ATP-dependent remodeling factors and histone modification enzymes 
act in sequence to fine-tune NR action.  PTMs of cofactors add an additional 
control by altering the affinity of the modified cofactor to the target NRs or to 
other cofactors.  This alteration changes the magnitude of transcriptional 
output of NR-regulated promoters.  Changes in cofactor expression, 
modification status, and enzymatic activities are often linked to disease states.  
Pharmaceutical research is being conducted to aid in the control of 
disease states.  Many of these pathological conditions involve pathways that 
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are responsible for gene expression through cofactor interactions.  People 
suffering from diabetes or obesity could benefit from drugs that target specific 
cofactor interactions.  A main stumbling block of this research is the body’s 
energy homeostasis.  There is no shortage in the possible drug targets for the 
treatment of diabetes and obesity.  However, a subtle change to the delicate 
balance of energy metabolism triggers a defense from the body itself.  This 
defense comes from the body’s perception of starvation and reduces the 
energy expenditure to compensate for the change.    
Further research into the interactions of cofactor involvement could 
lead to a better awareness of the pathology of some cancers.  Estrogens are a 
key steroid that act through the ER and are important regulators of breast 
cancer growth.  The receptor controls gene expression through the recruitment 
of transcriptional cofactors.  These transcriptional coafactors are involved 
with the protein--protein interactions that allow for the uncontrolled growth of 
breast cancers.  This illustrates the importance of the interactions of the ER 
with cofactors in breast cancer pathology.  The development of improved 
selective NR modulators will be useful for the prevention and treatment of 
cancer as well as other diseases. 
There are still major gaps in our understanding of the complexity of 
NR signaling events.  Many questions are being asked by researchers in the 
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field now.  What are the mechanisms of action of an individual coactivator?  
How are the engagement of complexes and the order of recruitment controlled 
on a promoter and cell-type-specific basis?  Providing a wide view of the 
transcriptional landscape will be accomplished by the use of ChIP assay.  This 
assay provides a depiction of the transcriptional methods, where the sequential 
or random recruitment of specific protein complexes can be analyzed.  These 
experiments will reveal the specific transcription activation and the proteins 
involved and potentially aid the development of novel therapies that will 
benefit treatment of diabetes, obesity and cancer. 
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